June 7, 2018 — IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
The Build-Blu delivery system is a disposable, next-generation, seed stranding device that will allow prostate brachytherapists to affordably build custom-configured strands with Cesium-131 in the operating room. This will allow clinicians to individualize the procedure to the patient’s anatomy in real time. IsoRay said this new product will provide an alternative solution to the approximately 25 percent of treatment facilities for the prostate market that are using intra-operative techniques.
According to IsoRay Chairman and CEO Thomas LaVoy, the intra-operative segment is estimated to account for approximately 25 percent, or $25 million, of the $100 million prostate brachytherapy market.
The Build-Blu delivery system product launch is scheduled for summer 2018.
For more information: www.isoray.com
October 19, 2026 
